SCHEMBL25422301

SCHEMBL25422301

CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)C(=O)C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NR1H2 P55055 2/20 0.47
ESR2 Q92731 1/20 0.46
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ADORA1 P30542 1/20 0.42
KDM4E B2RXH2 1/20 0.41
THRB P10828 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
HPGD P15428 1/20 0.41
EPHX2 P34913 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15200845 0.90 USP2 (0.41) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL17405125 0.90 MEN1 (0.47) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL18947196 0.85 DDB1 (0.40) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL31218507 0.85 CHRM2 (0.44) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL1968373 0.84 USP2 (0.46) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL13244889 0.84 USP2 (0.46) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL14800964 0.83 USP2 (0.52) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL20812242 0.83 NR1H2 (0.45) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL16419557 0.83 NR1H2 (0.46) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL22127628 0.83 MEN1 (0.48) NR1H2ESR2MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2025-09-02 US disclosed
WO-2024259171-A9 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-01-23 WO disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 US disclosed
WO-2024259171-A2 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed
EP-4452984-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF Molecure S.A. (PL) 2024-10-30 EP disclosed
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-07-13 US disclosed
WO-2023119233-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF KEAP1, NFE2L2, NQO1 USP2 588/4885SMN1; SMN2 3268/4885NR1H2 65/4885
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF USP7, USP28, USP1 USP2 4/4885SMN1; SMN2 2139/4885NR1H2 3238/4885
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof USP7, USP28, USP1 USP2 4/4885SMN1; SMN2 2139/4885NR1H2 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.